Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 1/2 4Phase 2 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Gynecologic 1

Conditions

Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 1038Cyclophosphamide 972Carboplatin 952Radiotherapy 890Bevacizumab 845Gemcitabine 817pembrolizumab 758Paclitaxel 738Docetaxel 733Oxaliplatin 704Capecitabine 646Fluorouracil 563Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 400Leucovorin 376Cytarabine 342Cetuximab 338Lenalidomide 326Trastuzumab 321Pemetrexed 314durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 277Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Depsipeptides × Clear all
NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

City of Hope Medical Center

Phase 2 Completed
12 enrolled 8 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00085527 2013-09-05

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

University of Chicago

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00299351 2006-03-06

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

Royal Marsden NHS Foundation Trust

Phase 2 Unknown
8 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡